Another common downside of these therapies, including past and currently-ongoing clinical trials in ANCA vasculitis (1), is that none of them specifically target anti-MPO autoimmunity to avoid complications due to their off-target, non-antigen-specific effects. The gene discussed is MPO; the disease is Autoimmunity.